rr-02: 医学论文审稿 — SOLSTICE Phase 2b Trial
任务信息
- 模块： writing
- 学科： Medicine
- 深度： L3
- 判定： PASS
来源论文
Aroda, Davies, Maaske et al., The Lancet (2026), DOI: 10.1016/S0140-6736(26)00802-0
输入
SOLSTICE is a phase 2b RCT evaluating elecoglipron (oral GLP-1 RA) in 404 adults with T2DM. HbA1c change ranged from −0.91% (5 mg) to −1.88% (75 mg) vs. −0.15% placebo at 26 weeks. Multiple dose regimens tested with varying escalation schedules. Open-label oral semaglutide 14 mg included as reference. GI AEs in 63–87% across elecoglipron doses.
输出 — 审稿报告
总结
SOLSTICE is a well-conducted phase 2b dose-ranging trial demonstrating clinically meaningful HbA1c reductions across all elecoglipron doses compared with placebo at 26 weeks, with a GI AE profile consistent with the GLP-1 RA class.
主要问题
1. Open-label semaglutide arm compromises double-blind integrity Participants and physicians in the semaglutide arm know treatment assignment, introducing expectation bias for subjective endpoints and complicating interpretation of the semaglutide reference data. Discuss this limitation explicitly; contextualize against published double-blind semaglutide data.
2. Dose-response interpretation confounded by escalation schedule The trial evaluates both fixed doses and escalated target doses with different titration rates. The 75 mg every-2-week vs. every-4-week regimens may produce different tolerability at the same dose. Test for a titration-rate effect at 75 mg before pooling.
3. HbA1c timing relative to dose escalation completion If participants in slower-escalation arms were still titrating at week 26, the HbA1c reduction may underestimate the treatment effect. Clarify endpoint timing relative to escalation completion.
次要问题
- 69% White participants limits generalizability — report subgroup data by ethnicity
- Report placebo-subtracted HbA1c changes with multiplicity adjustment
- Report hypoglycemia rates (relevant if background sulfonylurea/insulin use)
证据强度
| 论点 | 强度 |
|---|---|
| HbA1c reduction vs. placebo | 强 |
| GI tolerability | 强 |
| Efficacy relative to semaglutide | 弱 |
| Optimal dose identified | 充分 |
决定：小修
Fundamentally sound trial design; concerns addressable through additional analysis and discussion.
判定
PASS — Identifies real trial design concerns (open-label comparator, dose-escalation confounding, endpoint timing), evidence strength calibration appropriate, decision well-justified.